 This is a randomized, double blind, multicenter, placebo-controlled, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in subjects 6 to 12 years of age with ADHD using 2 doses of dasotraline 2 mgday and 4 mgday versus placebo over a 6 week treatment period. The study will consist of screening, treatment, and end of study visits. 